Evidence map›Paper›PMID 35058086›Full record

ArticleEuropean urology2022

What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy?

Longbin Xiong, Jane K Nguyen, Yulu Peng, Zhaohui Zhou, Kang Ning, Nan Jia, Jing Nie, Dongxiang Wen, Zeshen Wu, Gustavo Roversi and 31 more

Abstract read
PubMed Publisher
In one paragraph

Article in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Targeting a Novel AREGCell proliferation · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Round up.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors at 15 institutions in 2 countries.

Longbin XiongDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Jane K NguyenDepartment of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Yulu PengDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Zhaohui ZhouDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Kang NingDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Nan JiaState Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jing NieState Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Dongxiang WenState Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Zeshen WuDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Gustavo RoversiDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Diego Aguilar PalaciosDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Emily AbramczykDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Carlos Munoz-LopezDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Jack A CampbellDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
Yun CaoState Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Wencai LiDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Henan, China.
Xuepei ZhangDepartment of Urology, First Affiliated Hospital of Zhengzhou University, Henan, China.
Zhisong HeDepartment of Urology, Peking University First Hospital, Beijing, China.
Xiang LiDepartment of Urology, West China Hospital of Sichuan University, Sichuan, China.
Jiwei HuangDepartment of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China.
Jianzhong ShouDepartment of Urology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.
Jitao WuDepartment of Urology, Yantai Yuhuangding Hospital, Shandong, China.
Minfeng ChenDepartment of Urology, Xiangya Hospital of Central South University, Changsha, China.
Xiaofeng ChenDepartment of Urology, The First People's Hospital of Chenzhou, Hunan, China.
Jiaxuan ZhengDepartment of Pathology, Hainan General Hospital, Hainan, China.
Congjie XuDepartment of Pathology, Hainan General Hospital, Hainan, China.
Wen ZhongDepartment of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zaishang LiDepartment of Urology, Shenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China; Department of Urology, The Second Clinical College of Jinan University, Shenzhen, China.
Wen DongDepartment of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Juping ZhaoDepartment of Urology, Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, China.
Hailang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Junhang LuoDepartment of Urology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Jianye LiuDepartment of Urology, The Third Xiangya Hospital of Central South University, Hunan, China.
Fanghu SunDepartment of Urology, No. 1 Hospital of Lian Yungang, Jiangsu, China.
Hui HanDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Shengjie GuoDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Pei DongDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Fangjian ZhouDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Chunping YuDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: yuchp@sysucc.org.cn.
Steven C CampbellDepartment of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: Campbes3@ccf.org.
Zhiling ZhangDepartment of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: zhangzhl@sysucc.org.cn.
Cleveland Clinic · USSun Yat-sen University Cancer Center · CNFirst Affiliated Hospital of Zhengzhou University · CNSun Yat-sen University · CNSouthern Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University Shanghai Cancer Center · CNGuangzhou Medical University · CNHainan General Hospital · CNPeking University · CNShanghai Jiao Tong University · CNSichuan University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNWest China Hospital of Sichuan University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost partial nephrectomies (PNs) are performed with hilar occlusion to reduce blood loss and optimize visualization. However, the histologic status of the preserved renal parenchyma years after PN is unknown.

objectiveTo compare the histologic chronic kidney disease (CKD) score of renal parenchyma before and years after PN, and to explore factors associated with CKD-score increase and glomerular filtration rate (GFR) decline. DESIGN, SETTING, AND

participantsA retrospective review of 147 renal cell carcinoma patients who underwent PN and subsequent radical nephrectomy (RN) due to tumor recurrence was performed in 19 Chinese centers and Cleveland Clinic. Macroscopic normal renal parenchyma was evaluated at least 5 mm away from the tumor in PN specimens and at remote sites in RN specimens.

interventionPN/RN and ischemia. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Histologic CKD score (0-12) represents a summary of glomerular/tubular/interstitial/vascular status. Predictive factors for a substantial increase of CKD score (≥3) were evaluated by logistic regression. RESULTS AND LIMITATIONS: Sixty-five patients with all necessary data were analyzed. The median interval between PN and RN was 2.4 yr. Median durations of warm ischemia (n = 42) and hypothermia (n = 23) were both 23 min. The histologic CKD score was increased after RN in 47 (72%) patients, with 29 (45%) experiencing more substantial increase (≥3). There was no significant difference in the change of CKD score related to the type and duration of ischemia (p = 0.7 and p = 0.4, respectively) or interval from PN to RN (p > 0.9). However, patients with comorbidities of hypertension, diabetes, and/or pre-existing CKD (hypertension [HTN]/diabetes mellitus [DM]/CKD) demonstrated increased rate and extent of CKD-score increase. On univariate analysis, HTN/DM/CKD was the only predictor of a substantial CKD-score increase (odds ratio: 3.53 [1.12-11.1]). Decline of GFR was modest and similar between patients with/without a substantial CKD-score increase.

conclusionsWithin the context of conventional, limited durations of ischemia, histologic deterioration of preserved parenchyma after PN appears to be primarily due to pre-existing medical comorbidities rather than ischemia. A subsequent decline in renal function was mild and independent of histologic changes. PATIENT SUMMARY: After clamped PN, the preserved renal parenchyma demonstrated histologic deterioration in many cases, which correlated with the presence of comorbidities such as hypertension, diabetes mellitus, or chronic kidney disease. In contrast, the type and duration of ischemia did not correlate with histologic changes after PN, suggesting that ischemia insult had only limited impact on parenchyma deterioration.

Indexed as

Carcinoma, Renal CellDiabetes MellitusHypertensionKidney NeoplasmsRenal Insufficiency, ChronicFemaleGlomerular Filtration RateHumansIschemiaKidneyMaleNeoplasm Recurrence, LocalNephrectomyRetrospective StudiesChronic kidney diseaseIschemiaPartial nephrectomyPathological scoresRenal functional

Identifiers

PMID35058086
OpenAlexW4205275061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.